Puerto Rico’s medical cannabis debate now carries a number that reaches beyond dispensary sales: $53 million a year. An October fiscal analysis connects a proposed restriction on patient eligibility to taxes, jobs and public health funding across the island.
The figure comes from the legislature’s budget office, OPAL. It describes a maximum potential fiscal effect under a severe contraction scenario. It is not a bill for losses already incurred or a prediction that every dollar will disappear.
Beard Bros Media’s October 14 report brought the analysis into the cannabis news cycle. The full government report adds a clearer picture of the people and businesses behind the estimate, including 112,223 active patients in fiscal 2025.
The proposed change starts with patients
House Bill 1281 would narrow medical cannabis eligibility to people with certified terminal conditions. Debilitating conditions would qualify when directly associated with a certified terminal condition. That connection is central to the proposal.
A serious or debilitating diagnosis would not, by itself, satisfy the proposed terminal-condition requirement. The practical stakes therefore begin with who could remain in the program. Retail demand, licenses and tax collections follow from that access decision.
The original bill, introduced May 15, 2026, also proposes removing the additional licensing requirement for physicians to recommend medical cannabis. Those two changes move in different directions: a narrower eligible patient population and fewer cannabis-specific licensing steps for otherwise authorized doctors.
The new development is the fiscal assessment, dated October 2026. The bill’s introduction was months earlier. OPAL evaluates the proposal’s potential effects; its report does not establish that the proposed eligibility rules have become law.
For the cannabis community, that distinction keeps the focus where it belongs. A proposed restriction can have major consequences worth examining before implementation. It should not be described as a change patients are already required to follow.
A program with more than 112,000 active patients
OPAL’s full report, number 2027-107, uses data supplied by Puerto Rico’s medical cannabis regulatory board. It lists 112,223 active patients and 84 active authorized physicians for fiscal 2025. The patient count was 124,958 in fiscal 2022.
Those figures describe an established program already experiencing contraction. They also explain why eligibility is an industry-wide question. A large reduction in the people allowed to participate would reach the businesses serving them.
The board recorded 259,932 medical-condition registrations for fiscal 2025. That is a different measure from the patient count. One person can have more than one registered condition, so the registrations cannot be treated as separate individuals.
Within those registrations, the board identified 5,598 in categories most closely related to the proposal’s parameters. They included palliative care, cancer and several other conditions. OPAL compared that group with the active patient population to establish an illustrative proportion of roughly five percent.
The report does not turn those registrations into a definitive list of qualifying patients. A diagnosis category does not establish the proposed terminal certification, and overlapping registrations complicate the count. The resulting 95 percent reduction is a modeling parameter, not a completed review of individual eligibility.
What the $53 million calculation assumes
OPAL takes fiscal 2025 as its baseline and holds other program conditions constant. Its upper-bound scenario assumes the end of the program’s economic activity and associated government revenue bases. That is stronger than simply reducing each revenue line by 95 percent.
The office explains that available condition data cannot precisely establish how many patients would remain eligible or how much economic activity would survive. It therefore presents a maximum potential effect rather than a single forecast of the expected outcome.
The report’s executive summary and conclusion place the potential annual effect at approximately $53 million beginning in fiscal 2027. The biggest component is $23.8 million in sales and use taxes tied to dispensary sales. About $21.7 million belongs to the central-government portion and $2.1 million to municipalities.
Another $15.5 million comes from income taxes: approximately $7.9 million associated with workers and $7.6 million with corporations. License revenue contributes an estimated $7.1 million. Worker spending accounts for another $6 million in sales and use taxes, while inventory tax contributes about $600,000.
Together, those rounded components produce the headline total. They describe several ways a cannabis economy connects to public revenue. The figure is broader than dispensary sales tax alone, and it is much smaller than the value of all products sold.
The businesses and workers behind the revenue
The report records 363 active dispensaries and approximately $206.53 million in aggregate sales for fiscal 2025. Fiscal 2024 sales were about $211.87 million. These are the operating figures beneath the tax calculation, rather than a projection of future market growth.
Employment requires a separate distinction. The regulatory board supplied a total of 2,326 direct jobs, including management and other employees. For its broader economic calculation, OPAL used an assumption of approximately 5,500 jobs, drawing on a retailers’ organization’s estimate that includes wider employment effects.
The larger figure should not become a claim that the board counted 5,500 cannabis employees. Direct employment, indirect work and spending-supported jobs measure different relationships. Keeping them separate makes the human stakes more credible.
For people working in cannabis, eligibility policy can become a workplace issue long before a storefront closes. Employers depend on the customer base the legal program permits. A restriction that changes that base therefore deserves attention from workers as well as business owners.
High Rise’s cannabis jobs board follows the employment side of the industry. Puerto Rico’s assessment is a reminder that a job market rests on more than brand expansion: the rules defining legal participation also shape its foundation.
Where public health funding enters the picture
Some cannabis revenue is directed toward specific public purposes. OPAL identifies a statutory allocation to the Trauma Hospital at the Río Piedras Medical Center equal to ten percent of the relevant sales and use tax receipts.
Under the report’s scenario, resources for that hospital could decline by approximately $2.2 million annually. The office also estimates a potential $3.9 million annual reduction for the fund serving people with remediable catastrophic illnesses, using the historical relationship between transfers and license receipts.
These figures describe where lost revenue would be felt. They are not extra losses to add on top of the $53 million estimate. Adding them again would inflate the total and obscure the connection between a revenue stream and its eventual use.
California offers a separate example of cannabis revenue supporting public programs. High Rise’s coverage of California’s $227 million in Proposition 64 grants examines that state’s allocations. Puerto Rico has different laws, recipients and fiscal assumptions; the shared point is that cannabis funding can reach well outside the retail counter.
The debate now has a more concrete starting point
OPAL’s role is consultative. The office explicitly says its analysis does not endorse or reject the legislation. Its contribution is a documented account of the program and a bounded estimate of what a severe contraction could mean.
That gives lawmakers and the public several concrete issues to address: the eligibility language, the number of people affected, the activity that might remain and the revenue supporting public services. None is answered by repeating the largest number alone.
The report also makes the patient question impossible to separate from the business question. The same access rules connect a person’s participation, a dispensary’s customers, a worker’s income and a hospital’s allocated funding. Debating one part requires acknowledging the others.
For continued coverage, the High Rise cannabis media directory is a starting point for finding reporting across the industry. In Puerto Rico, the next meaningful developments will be documented changes to the proposal, legislative action or new evidence about its effects. The October assessment has already made the stakes more specific.